The Challenges and Promise of Neuroimaging in Psychiatry

Neuron

Volumn 73, Issue 1, 2012, Pages 8-22

  Linden, David E J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR; FLUORODEOXYGLUCOSE F 18; QUETIAPINE; RADIOLIGAND; SEROTONIN TRANSPORTER;

ALZHEIMER DISEASE; BINDING SITE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE PROBE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MAGNETOENCEPHALOGRAPHY; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MOLECULAR IMAGING; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; MENTAL DISORDERS; NEUROIMAGING; PSYCHIATRY;

EID: 84855732200     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2011.12.014     Document Type: Review

References (136)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., van Dyck C.H., Charney D.S., Innis R.B., Laruelle M. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 1998, 155:761-767.
2. Abi-Dargham A., Kegeles L.S., Zea-Ponce Y., Mawlawi O., Martinez D., Mitropoulou V., O'Flynn K., Koenigsberg H.W., Van Heertum R., Cooper T., et al. Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol. Psychiatry 2004, 55:1001-1006.
3. Alakurtti K., Aalto S., Johansson J.J., Någren K., Tuokkola T., Oikonen V., Laine M., Rinne J.O. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J. Cereb. Blood Flow Metab. 2011, 31:155-165.
4. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, American Psychiatric Association, Washington, DC. Fourth Edition.
5. Barch D.M., Mathalon D.H. Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: psychometric and quality assurance considerations. Biol. Psychiatry 2011, 70:13-18.
6. Beutel M.E., Stern E., Silbersweig D.A. The emerging dialogue between psychoanalysis and neuroscience: neuroimaging perspectives. J. Am. Psychoanal. Assoc. 2003, 51:773-801.
7. Bigos K.L., Weinberger D.R. Imaging genetics-days of future past. Neuroimage 2010, 53:804-809.
8. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004, 29:1943-1961.
9. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95. Biomarkers Definitions Working Group.
10. Blokland G.A., McMahon K.L., Thompson P.M., Martin N.G., de Zubicaray G.I., Wright M.J. Heritability of working memory brain activation. J.Neurosci. 2011, 31:10882-10890.
11. Boy F., Evans C.J., Edden R.A., Lawrence A.D., Singh K.D., Husain M., Sumner P. Dorsolateral prefrontal γ-aminobutyric acid in men predicts individual differences in rash impulsivity. Biol. Psychiatry 2011, 70:866-872.
12. Braun U., Plichta M.M., Esslinger C., Sauer C., Haddad L., Grimm O., Mier D., Mohnke S., Heinz A., Erk S., et al. Test-retest reliability of resting-state connectivity network characteristics using fMRI and graph theoretical measures. Neuroimage 2012, 59:1404-1412.
13. Chen Z.Y., Jing D., Bath K.G., Ieraci A., Khan T., Siao C.J., Herrera D.G., Toth M., Yang C., McEwen B.S., et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006, 314:140-143.
14. Clark D.A., Beck A.T. Cognitive theory and therapy of anxiety and depression: convergence with neurobiological findings. Trends Cogn. Sci. (Regul. Ed.) 2010, 14:418-424.
15. Craddock R.C., Holtzheimer P.E., Hu X.P., Mayberg H.S. Disease state prediction from resting state functional connectivity. Magn. Reson. Med. 2009, 62:1619-1628.
16. Craddock N., Jones L., Jones I.R., Kirov G., Green E.K., Grozeva D., Moskvina V., Nikolov I., Hamshere M.L., Vukcevic D., et al. Strong genetic evidence for a selective influence of GABAA receptors on a component of the bipolar disorder phenotype. Mol. Psychiatry 2010, 15:146-153. Wellcome Trust Case Control Consortium (WTCCC).
17. Cummings J.L. Integrating ADNI results into Alzheimer's disease drug development programs. Neurobiol. Aging 2010, 31:1481-1492.
18. Davatzikos C., Shen D., Gur R.C., Wu X., Liu D., Fan Y., Hughett P., Turetsky B.I., Gur R.E. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Arch. Gen. Psychiatry 2005, 62:1218-1227.
19. deCharms R.C. Applications of real-time fMRI. Nat. Rev. Neurosci. 2008, 9:720-729.
20. deCharms R.C., Maeda F., Glover G.H., Ludlow D., Pauly J.M., Soneji D., Gabrieli J.D., Mackey S.C. Control over brain activation and pain learned by using real-time functional MRI. Proc. Natl. Acad. Sci. USA 2005, 102:18626-18631.
21. De Martino F., Valente G., Staeren N., Ashburner J., Goebel R., Formisano E. Combining multivariate voxel selection and support vector machines for mapping and classification of fMRI spatial patterns. Neuroimage 2008, 43:44-58.
22. DeRubeis R.J., Siegle G.J., Hollon S.D. Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat. Rev. Neurosci. 2008, 9:788-796.
23. De Stefano N., Filippi M., Miller D., Pouwels P.J., Rovira A., Gass A., Enzinger C., Matthews P.M., Arnold D.L. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology 2007, 69:1942-1952.
24. DeStefano A.L., Seshadri S., Beiser A., Atwood L.D., Massaro J.M., Au R., Wolf P.A., DeCarli C. Bivariate heritability of total and regional brain volumes: the Framingham Study. Alzheimer Dis. Assoc. Disord. 2009, 23:218-223.
25. Dierks T., Linden D.E., Jandl M., Formisano E., Goebel R., Lanfermann H., Singer W. Activation of Heschl's gyrus during auditory hallucinations. Neuron 1999, 22:615-621.
26. Ecker C., Marquand A., Mourão-Miranda J., Johnston P., Daly E.M., Brammer M.J., Maltezos S., Murphy C.M., Robertson D., Williams S.C., Murphy D.G. Describing the brain in autism in five dimensions-magnetic resonance imaging-assisted diagnosis of autism spectrum disorder using a multiparameter classification approach. J. Neurosci. 2010, 30:10612-10623.
27. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
28. Erk S., Meyer-Lindenberg A., Schnell K., Opitz von Boberfeld C., Esslinger C., Kirsch P., Grimm O., Arnold C., Haddad L., Witt S.H., et al. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch. Gen. Psychiatry 2010, 67:803-811.
29. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., Haddad L., Mier D., Opitz von Boberfeld C., Raab K., et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
30. Esslinger C., Walter H., Kirsch P., Erk S., Schnell K., Arnold C., Haddad L., Mier D., Opitz von Boberfeld C., Raab K., et al. Neural mechanisms of a genome-wide supported psychosis variant. Science 2009, 324:605.
31. First M.B. Paradigm shifts and the development of the diagnostic and statistical manual of mental disorders: past experiences and future aspirations. Can. J. Psychiatry 2010, 55:692-700.
32. Frank M.J., Fossella J.A. Neurogenetics and pharmacology of learning, motivation, and cognition. Neuropsychopharmacology 2011, 36:133-152.
33. Fu C.H., Mourao-Miranda J., Costafreda S.G., Khanna A., Marquand A.F., Williams S.C., Brammer M.J. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol. Psychiatry 2008, 63:656-662.
34. Gaetz W., Roberts T.P., Singh K.D., Muthukumaraswamy S.D. Functional and structural correlates of the aging brain: Relating visual cortex (V1) gamma band responses to age-related structural change. Hum. Brain Mapp. 2011, in press. Published online July 18, 2011.
35. George M.S., Aston-Jones G. Noninvasive techniques for probing neurocircuitry and treating illness: vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS). Neuropsychopharmacology 2010, 35:301-316.
36. Geramita M., van der Veen J.W., Barnett A.S., Savostyanova A.A., Shen J., Weinberger D.R., Marenco S. Reproducibility of prefrontal γ-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed. 2011, 24:1089-1098.
37. Gerardin E., Chételat G., Chupin M., Cuingnet R., Desgranges B., Kim H.S., Niethammer M., Dubois B., Lehéricy S., Garnero L., et al. Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage 2009, 47:1476-1486. Alzheimer's Disease Neuroimaging Initiative.
38. Gonzalez-Burgos G., Kroener S., Seamans J.K., Lewis D.A., Barrionuevo G. Dopaminergic modulation of short-term synaptic plasticity in fast-spiking interneurons of primate dorsolateral prefrontal cortex. J. Neurophysiol. 2005, 94:4168-4177.
39. Gottesman I.I., Gould T.D. The endophenotype concept inpsychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
40. Gountouna V.E., Job D.E., McIntosh A.M., Moorhead T.W., Lymer G.K., Whalley H.C., Hall J., Waiter G.D., Brennan D., McGonigle D.J., et al. Functional Magnetic Resonance Imaging (fMRI) reproducibility and variance components across visits and scanning sites with a finger tapping task. Neuroimage 2010, 49:552-560.
41. Greicius M. Resting-state functional connectivity in neuropsychiatric disorders. Curr. Opin. Neurol. 2008, 21:424-430.
42. Haenschel C., Linden D.E.J. Neurophysiology of Cognitive Dysfunction in Schizophrenia. Handbook of Schizophrenia Spectrum Disorders 2011, Springer, Heidelberg. M.S. Ritsner (Ed.).
43. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
44. Hampel H., Wilcock G., Andrieu S., Aisen P., Blennow K., Broich K., Carrillo M., Fox N.C., Frisoni G.B., Isaac M., et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2011, 95:579-593. for the Oxford Task Force Group.
45. Hasler G., Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 2011, 16:604-619.
46. Heinz A., Siessmeier T., Wrase J., Hermann D., Klein S., Grüsser S.M., Flor H., Braus D.F., Buchholz H.G., Gründer G., et al. Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am. J. Psychiatry 2004, 161:1783-1789.
47. Hibar D., Kohannim O., Stein J., Chiang M.-C., Thompson P. Multilocus genetic analysis of brain images. Front. Gene. 2011, 2:73.
48. Hibar D.P., Stein J.L., Kohannim O., Jahanshad N., Saykin A.J., Shen L., Kim S., Pankratz N., Foroud T., Huentelman M.J., et al. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage 2011, 56:1875-1891. Alzheimer's Disease Neuroimaging Initiative.
49. Hoeft F., Lightbody A.A., Hazlett H.C., Patnaik S., Piven J., Reiss A.L. Morphometric spatial patterns differentiating boys with fragile X syndrome, typically developing boys, and developmentally delayed boys aged 1 to 3 years. Arch. Gen. Psychiatry 2008, 65:1087-1097.
50. Hoffman R.E., Hawkins K.A., Gueorguieva R., Boutros N.N., Rachid F., Carroll K., Krystal J.H. Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch. Gen. Psychiatry 2003, 60:49-56.
51. Holmans P. Statistical methods for pathway analysis of genome-wide data for association with complex genetic traits. Adv. Genet. 2010, 72:141-179.
52. Ingalhalikar M., Kanterakis S., Gur R., Roberts T.P., Verma R. DTI based diagnostic prediction of a disease via pattern classification. Med Image Comput Comput Assist Interv 2010, 13:558-565.
53. Inkster B., Nichols T.E., Saemann P.G., Auer D.P., Holsboer F., Muglia P., Matthews P.M. Pathway-based approaches to imaging genetics association studies: Wnt signaling, GSK3beta substrates and major depression. Neuroimage 2010, 53:908-917.
54. Ioannidis J.P. Why most published research findings are false. PLoS Med. 2005, 2:e124.
55. Ioannidis J.P. Excess significance bias in the literature on brain volume abnormalities. Arch. Gen. Psychiatry 2011, 68:773-780.
56. Isaksson A., Wallman M., Goeransson H., Gustafsson M.G. Cross-validation and bootstrapping are unreliable in small sample classification. Pattern Recognit. Lett. 2008, 29:1960-1965.
57. Jagust W.J., Bandy D., Chen K., Foster N.L., Landau S.M., Mathis C.A., Price J.C., Reiman E.M., Skovronsky D., Koeppe R.A. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010, 6:221-229. Alzheimer's Disease Neuroimaging Initiative.
58. Jardri R., Pouchet A., Pins D., Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am. J. Psychiatry 2011, 168:73-81.
59. Johnston S.J., Boehm S.G., Healy D., Goebel R., Linden D.E. Neurofeedback: A promising tool for the self-regulation of emotion networks. Neuroimage 2010, 49:1066-1072.
60. Johnstone E.C., Crow T.J., Frith C.D., Husband J., Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976, 2:924-926.
61. Kandel E.R. Biology and the future of psychoanalysis: a new intellectual framework for psychiatry revisited. Am. J. Psychiatry 1999, 156:505-524.
62. Karayiorgou M., Simon T.J., Gogos J.A. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction and schizophrenia. Nat. Rev. Neurosci. 2010, 11:402-416.
63. Kegeles L.S., Slifstein M., Frankle W.G., Xu X., Hackett E., Bae S.A., Gonzales R., Kim J.H., Alvarez B., Gil R., et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008, 33:3111-3125.
64. Kirov G., Pocklington A.J., Holmans P., Ivanov D., Ikeda M., Ruderfer D., Moran J., Chambert K., Toncheva D., Georgieva L., et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol. Psychiatry 2011, in press. Published online November 15, 2011. 10.1038/Menlo Park.2011.154.
65. Kleppisch T., Feil R. cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 2009, 191:549-579.
66. Klöppel S., Stonnington C.M., Chu C., Draganski B., Scahill R.I., Rohrer J.D., Fox N.C., Jack C.R., Ashburner J., Frackowiak R.S. Automatic classification of MR scans in Alzheimer's disease. Brain 2008, 131:681-689.
67. Klosterkötter J., Schultze-Lutter F., Bechdolf A., Ruhrmann S. Prediction and prevention of schizophrenia: what has been achieved and where to go next?. World Psychiatry 2011, 10:165-174.
68. Koutsouleris N., Meisenzahl E.M., Davatzikos C., Bottlender R., Frodl T., Scheuerecker J., Schmitt G., Zetzsche T., Decker P., Reiser M., et al. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch. Gen. Psychiatry 2009, 66:700-712.
69. Krishnan V., Nestler E.J. Linking molecules to mood: new insight into the biology of depression. Am. J. Psychiatry 2010, 167:1305-1320.
70. Kruggel F., Turner J., Muftuler L.T. Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort. Neuroimage 2010, 49:2123-2133. Alzheimer's Disease Neuroimaging Initiative.
71. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA 1996, 93:9235-9240.
72. Laxton A.W., Tang-Wai D.F., McAndrews M.P., Zumsteg D., Wennberg R., Keren R., Wherrett J., Naglie G., Hamani C., Smith G.S., Lozano A.M. A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann. Neurol. 2010, 68:521-534.
73. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000, 28:325-334.
74. Linden D.E. How psychotherapy changes the brain-the contribution of functional neuroimaging. Mol. Psychiatry 2006, 11:528-538.
75. Linden D.E. Brain imaging and psychotherapy: methodological considerations and practical implications. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(Suppl 5):71-75.
76. Linden D.E., Thornton K., Kuswanto C.N., Johnston S.J., van de Ven V., Jackson M.C. The brain's voices: comparing nonclinical auditory hallucinations and imagery. Cereb. Cortex 2011, 21:330-337.
77. Lovinger D.M. Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum. Neuropharmacology 2010, 58:951-961.
78. Luck S.J., Mathalon D.H., O'Donnell B.F., Hämäläinen M.S., Spencer K.M., Javitt D.C., Uhlhaas P.J. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol. Psychiatry 2011, 70:28-34.
79. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., Schwalb J.M., Kennedy S.H. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
80. McDonald C., Marshall N., Sham P.C., Bullmore E.T., Schulze K., Chapple B., Bramon E., Filbey F., Quraishi S., Walshe M., Murray R.M. Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am. J. Psychiatry 2006, 163:478-487.
81. McGorry P.D., Purcell R., Goldstone S., Amminger G.P. Age of onset and timing of treatment for mental and substance use disorders: implications for preventive intervention strategies and models of care. Curr. Opin. Psychiatry 2011, 24:301-306.
82. Meyer J.H. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 2007, 32:86-102.
83. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010, 468:194-202.
84. Meyer-Lindenberg A., Mervis C.B., Berman K.F. Neural mechanisms in Williams syndrome: a unique window to genetic influences on cognition and behaviour. Nat. Rev. Neurosci. 2006, 7:380-393.
85. Mier D., Kirsch P., Meyer-Lindenberg A. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis. Mol. Psychiatry 2010, 15:918-927.
86. Moore H., West A.R., Grace A.A. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia. Biol. Psychiatry 1999, 46:40-55.
87. Mosconi L., Berti V., Glodzik L., Pupi A., De Santi S., de Leon M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J. Alzheimers Dis. 2010, 20:843-854.
88. Munafò M.R., Brown S.M., Hariri A.R. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol. Psychiatry 2008, 63:852-857.
89. Muthukumaraswamy S.D., Edden R.A., Jones D.K., Swettenham J.B., Singh K.D. Resting GABA concentration predicts peak gamma frequency and fMRI amplitude in response to visual stimulation in humans. Proc. Natl. Acad. Sci. USA 2009, 106:8356-8361.
90. Muthukumaraswamy S.D., Singh K.D., Swettenham J.B., Jones D.K. Visual gamma oscillations and evoked responses: variability, repeatability and structural MRI correlates. Neuroimage 2010, 49:3349-3357.
91. Nestler E.J., Hyman S.E., Malenka R.C. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience 2009, McGraw-Hill Medical, New York. Second Edition.
92. Nikisch G., Baumann P., Kiessling B., Reinert M., Wiedemann G., Kehr J., Mathé A.A., Piel M., Roesch F., Weisser H., et al. Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine. J. Psychiatr. Res. 2010, 44:754-759.
93. Nikolaus S., Antke C., Müller H.W. Invivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav. Brain Res. 2009, 204:32-66.
94. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011, 17:97-103.
95. O'Donoghue T., Morris D.W., Fahey C., Costa A.D., Foxe J.J., Hoerold D., Tropea D., Gill M., Corvin A., Donohoe G. A NOS1 variant implicated in cognitive performance influences evoked neural responses during a high density EEG study of early visual perception. Hum. Brain Mapp. 2011, in press. Published online April 21, 2011.
96. O'Donovan M.C., Craddock N., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., Hamshere M., Carroll L., Georgieva L., et al. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 2008, 40:1053-1055. Molecular Genetics of Schizophrenia Collaboration.
97. Ochsner K.N., Gross J.J. The cognitive control of emotion. Trends Cogn. Sci. (Regul. Ed.) 2005, 9:242-249.
98. Oler J.A., Fox A.S., Shelton S.E., Rogers J., Dyer T.D., Davidson R.J., Shelledy W., Oakes T.R., Blangero J., Kalin N.H. Amygdalar and hippocampal substrates of anxious temperament differ in their heritability. Nature 2010, 466:864-868.
99. Owen M.J., Craddock N., O'Donovan M.C. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch. Gen. Psychiatry 2010, 67:667-673.
100. Peper J.S., Brouwer R.M., Boomsma D.I., Kahn R.S., Hulshoff Pol H.E. Genetic influences on human brain structure: a review of brain imaging studies in twins. Hum. Brain Mapp. 2007, 28:464-473.
101. Phillips M.L., Ladouceur C.D., Drevets W.C. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol. Psychiatry 2008, 13:829. 833-857.
102. Potkin S.G., Guffanti G., Lakatos A., Turner J.A., Kruggel F., Fallon J.H., Saykin A.J., Orro A., Lupoli S., Salvi E., et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS ONE 2009, 4:e6501. Alzheimer's Disease Neuroimaging Initiative.
103. Potkin S.G., Turner J.A., Fallon J.A., Lakatos A., Keator D.B., Guffanti G., Macciardi F. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Mol. Psychiatry 2009, 14:416-428.
104. Potkin S.G., Turner J.A., Guffanti G., Lakatos A., Fallon J.H., Nguyen D.D., Mathalon D., Ford J., Lauriello J., Macciardi F. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Schizophr. Bull. 2009, 35:96-108. FBIRN.
105. Rathi Y., Malcolm J., Michailovich O., Goldstein J., Seidman L., McCarley R.W., Westin C.F., Shenton M.E. Biomarkers for identifying first-episode schizophrenia patients using diffusion weighted imaging. Med Image Comput Comput Assist Interv 2010, 13:657-665.
106. Ringman J.M., Medina L.D., Braskie M., Rodriguez-Agudelo Y., Geschwind D.H., Macias-Islas M.A., Cummings J.L., Bookheimer S. Effects of risk genes on BOLD activation in presymptomatic carriers of familial Alzheimer's disease mutations during a novelty encoding task. Cereb. Cortex 2011, 21:877-883.
107. Ripke S., Sanders A.R., Kendler K.S., Levinson D.F., Sklar P., Holmans P.A., Lin D.Y., Duan J., Ophoff R.A., Andreassen O.A., et al. Genome-wide association study identifies five new schizophrenia loci. Nat. Genet. 2011, 43:969-976. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium.
108. Roffman J.L., Marci C.D., Glick D.M., Dougherty D.D., Rauch S.L. Neuroimaging and the functional neuroanatomy of psychotherapy. Psychol. Med. 2005, 35:1385-1398.
109. Rotarska-Jagiela A., Schönmeyer R., Oertel V., Haenschel C., Vogeley K., Linden D.E. The corpus callosum in schizophrenia-volume and connectivity changes affect specific regions. Neuroimage 2008, 39:1522-1532.
110. Sánchez-Panchuelo R.M., Francis S.T., Schluppeck D., Bowtell R.W. Correspondence of human visual areas identified using functional and anatomical MRI invivo at 7 T. J. Magn. Reson. Imaging 2011, in press. Published online September 30, 2010.
111. Savitz J.B., Drevets W.C. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 2009, 164:300-330.
112. Scheinin N.M., Scheinin M., Rinne J.O. Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Q. J. Nucl. Med. Mol. Imaging 2011, 55:265-279.
113. Shen L., Kim S., Risacher S.L., Nho K., Swaminathan S., West J.D., Foroud T., Pankratz N., Moore J.H., Sloan C.D., et al. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010, 53:1051-1063. Alzheimer's Disease Neuroimaging Initiative.
114. Shifman S., Bhomra A., Smiley S., Wray N.R., James M.R., Martin N.G., Hettema J.M., An S.S., Neale M.C., van den Oord E.J., et al. A whole genome association study of neuroticism using DNA pooling. Mol. Psychiatry 2008, 13:302-312.
115. Shotbolt P., Stokes P.R., Owens S.F., Toulopoulou T., Picchioni M.M., Bose S.K., Murray R.M., Howes O.D. Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol. Med. 2011, 41:2331-2338.
116. Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootoonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995, 378:176-179.
117. Simmons J.P., Nelson L.D., Simonsohn U. False-positive psychology: undisclosed flexibility in data collection and analysis allows presenting anything as significant. Psychol. Sci. 2011, 22:1359-1366.
118. Soares H.D. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development. Curr. Opin. Investig. Drugs 2010, 11:795-801.
119. Stein J.L., Hibar D.P., Madsen S.K., Khamis M., McMahon K.L., de Zubicaray G.I., Hansell N.K., Montgomery G.W., Martin N.G., Wright M.J., et al. Genome-wide association reveals dopamine-related genetic effects on caudate volume. Mol. Psychiatry 2011, 16:881.
120. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 2006, 59:929-939.
121. Subramanian L., Hindle J.V., Johnston S., Roberts M.V., Husain M., Goebel R., Linden D. Real-time functional magnetic resonance imaging neurofeedback for treatment of Parkinson's disease. J. Neurosci. 2011, 31:16309-16317.
122. Sullivan P.F., Kendler K.S., Neale M.C. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch. Gen. Psychiatry 2003, 60:1187-1192.
123. Takano A. The application of PET technique for the development and evaluation of novel antipsychotics. Curr. Pharm. Des. 2010, 16:371-377.
124. Urban N., Abi-Dargham A. Neurochemical imaging in schizophrenia. Curr Top Behav Neurosci 2010, 4:215-242.
125. Venkatasubramanian G., Jayakumar P.N., Reddy V.V., Reddy U.S., Gangadhar B.N., Keshavan M.S. Corpus callosum deficits in antipsychotic-naïve schizophrenia: evidence for neurodevelopmental pathogenesis. Psychiatry Res. 2010, 182:141-145.
126. Vounou M., Nichols T.E., Montana G. Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage 2010, 53:1147-1159. Alzheimer's Disease Neuroimaging Initiative.
127. Vyas N.S., Patel N.H., Nijran K.S., Al-Nahhas A., Puri B.K. The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia. Expert Rev. Neurother. 2011, 11:37-51.
128. Weiskopf N., Veit R., Erb M., Mathiak K., Grodd W., Goebel R., Birbaumer N. Physiological self-regulation of regional brain activity using real-time functional magnetic resonance imaging (fMRI): methodology and exemplary data. Neuroimage 2003, 19:577-586.
129. Williams N.M., Zaharieva I., Martin A., Langley K., Mantripragada K., Fossdal R., Stefansson H., Stefansson K., Magnusson P., Gudmundsson O.O., et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010, 376:1401-1408.
130. Winterer G., Weinberger D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004, 27:683-690.
131. Wolf C., Linden D.E. Biological pathways to adaptability - interactions between genome, epigenome, nervous system and environment for adaptive behavior. Genes Brain Behav. 2011, in press. Published online November 3, 1011. 10.1111/j.1601-183X.2011.00752.x.
132. Wong D.F., Tauscher J., Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009, 34:187-203.
133. Wood S.J., Pantelis C., Velakoulis D., Yücel M., Fornito A., McGorry P.D. Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr. Bull. 2008, 34:322-329.
134. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, World Health Organisation, WHO, Geneva.
135. Xu G., Rowley H.A., Wu G., Alsop D.C., Shankaranarayanan A., Dowling M., Christian B.T., Oakes T.R., Johnson S.C. Reliability and precision of pseudo-continuous arterial spin labeling perfusion MRI on 3.0T and comparison with 15O-water PET in elderly subjects at risk for Alzheimer's disease. NMR Biomed. 2010, 23:286-293.
136. 11C]raclopride-binding potential in nontreatment-seeking alcoholics. Synapse 2011, 65:553-561.